Human immunodeficiency virus type 1 T-cell epitope (HIV-1 T-cell epitope)

Human immunodeficiency virus type 1 (HIV-1) T-cell epitopes are short peptide sequences derived from the virus's proteome, including structural proteins like Gag and functional enzymes like Pol. These epitopes are processed by host cells and presented on the cell surface bound to Major Histocompatibility Complex (MHC) molecules, where they are recognized by T-cell receptors (TCRs) [1][2]. CD8+ T-cell epitopes are typically 8-11 amino acids long and presented by MHC Class I, triggering the destruction of infected cells, while CD4+ T-cell epitopes are usually longer and presented by MHC Class II to coordinate the broader immune response [2][3]. In therapeutic development, these epitopes are the primary targets for T-cell based vaccines and immunotherapies aimed at controlling viral replication and establishing a functional cure [4]. However, the high mutation rate of HIV-1 leads to frequent 'immune escape,' where the virus alters these epitopes to evade recognition, posing a major challenge for drug design [5].

Other names

HIV-1 peptide antigenHIV-1 CTL epitopeHIV-1 helper T-cell epitopeHIV-1 MHC-restricted peptideHuman immunodeficiency virus type 1 cytotoxic T-lymphocyte epitope

Induction of antigen-specific CD4+ and CD8+ T-cell responses to identify and eliminate cells expressing viral proteins